TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
A P2Y12 inhibitor-based monotherapy after a short period of dual antiplatelet therapy is emerging as a plausible strategy to decrease bleeding events in high-risk patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Ticagrelor With Aspirin or Alone in High-Risk Pati...
Main Authors: | Johny Nicolas, Usman Baber, Roxana Mehran |
---|---|
Format: | Article |
Language: | English |
Published: |
Radcliffe Medical Media
2020-05-01
|
Series: | US Cardiology Review |
Online Access: | https://www.uscjournal.com/articleindex/usc.2019.02 |
Similar Items
-
Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
by: Thomas W. Johnson, et al.
Published: (2020-12-01) -
Ticagrelor monotherapy after a short course of dual antiplatelet therapy with ticagrelor plus aspirin following percutaneous coronary intervention in patients with versus without diabetes mellitus: a meta-analysis of randomized trials
by: Chen Ning, et al.
Published: (2024-03-01) -
Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
by: Bin YANG, et al.
Published: (2018-07-01) -
Body mass index affecting ticagrelor monotherapy vs. ticagrelor with aspirin in patients with acute coronary syndrome: A pre-specified sub-analysis of the TICO randomized trial
by: Byung Gyu Kim, et al.
Published: (2023-03-01) -
Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
by: Francesco Condello, et al.
Published: (2021-11-01)